Trial Profile
A Randomized, Controlled, Multi-Centre Trial on the Effects of Dual-release Hydrocortisone Preparations Versus Conventional Glucocorticoid Replacement Therapy in Patients Affected by Primary and Secondary Adrenal Insufficiency. DREAM Trial.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Hydrocortisone (Primary)
- Indications Adrenal insufficiency
- Focus Therapeutic Use
- Acronyms DREAM
- 26 Jun 2017 Status changed from recruiting to completed.
- 08 Mar 2015 Results presented at The 97th Annual Meeting of the Endocrine Society.
- 04 Nov 2014 New trial record